JANX
Janux Therapeutics Inc
NASDAQ: JANX · HEALTHCARE · BIOTECHNOLOGY
$14.11
-2.69% today
Updated 2026-04-29
Market cap
$882.06M
P/E ratio
—
P/S ratio
88.21x
EPS (TTM)
$-1.83
Dividend yield
—
52W range
$12 – $35
Volume
1.0M
Janux Therapeutics Inc (JANX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+11.9%
Last 4 quarters
Revenue YoY growth
-192.6%
Most recent quarter
EPS YoY growth
-41.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-0.7%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
-5.6%
2025-08-07
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-06 | $-0.51 | +27.1% | $13.97 | $13.98 | +0.1% |
| 2025-11-11 | $-0.39 | +36.8% | $27.59 | $28.52 | +3.4% |
| 2025-08-07 | $-0.55 | -19.3% | $24.18 | $22.83 | -5.6% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.70 | $-0.51 | +27.1% | $7.88M | -192.6% |
| 2025-09-30 | $-0.62 | $-0.39 | +36.8% | $10.00M | +2177.9% |
| 2025-06-30 | $-0.46 | $-0.55 | -19.3% | — | — |
| 2025-03-31 | $-0.39 | $-0.38 | +3.0% | — | — |
| 2024-12-31 | $-0.43 | $-0.36 | +15.6% | $-8.51M | -445.9% |
| 2024-09-30 | $-0.33 | $-0.51 | -54.5% | $439000.00 | -82.6% |
| 2024-06-30 | $-0.31 | $-0.11 | +64.5% | $8.90M | +741.7% |
| 2024-03-31 | $-0.33 | $-0.30 | +9.1% | $1.25M | -38.9% |
| 2023-12-31 | $-0.41 | $-0.25 | +39.0% | $2.46M | — |
| 2023-09-30 | $-0.47 | $-0.25 | +46.8% | $2.52M | — |
| 2023-06-30 | $-0.52 | $-0.42 | +19.2% | $1.06M | — |
| 2023-03-31 | $-0.49 | $-0.42 | +14.3% | $2.05M | — |
Frequently asked questions
Has Janux Therapeutics Inc beaten earnings estimates?
Janux Therapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +11.9% over the last 4 quarters.
How does JANX stock react to earnings?
JANX stock has moved an average of -0.7% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Janux Therapeutics Inc's revenue growth rate?
Janux Therapeutics Inc reported year-over-year revenue growth of -192.6% in its most recent quarter, with EPS growing -41.7% year-over-year.